NCT04272944View on ClinicalTrials.gov

A Study of MSB2311 in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 13, 2018

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions
Advanced Solid Tumor
Interventions
DRUG

10 mg/kg Q2W

10 mg/kg MSB2311 every two weeks

DRUG

20 mg/kg Q3W

20 mg/kg MSB2311 every three weeks.

Trial Locations (1)

215123

Mabspace Biosciences (Suzhou) Co., Ltd., Suzhou

All Listed Sponsors
lead

Suzhou Transcenta Therapeutics Co., Ltd.

INDUSTRY

NCT04272944 - A Study of MSB2311 in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter